Peripheral Neurological Disorders Research Articles

COVID-19 disease severity and affectations in electroneuromyographic studies

IntroductionEmerging research has highlighted COVID-19's profound impact on the nervous system, with ongoing debate regarding its severity and the emergence of peripheral neurological disorders. This study delves into the correlation between COVID-19 severity and electromyographic abnormalities in hospitalized patients, aiming to elucidate the nature and extent of neuromuscular dysfunction associated with the disease. MethodsIn a retrospective, cross-sectional, observational study, we analyzed data from 170 patients treated at the North Physical Medicine and Rehabilitation Unit between July 2020 and April 2021. Post-COVID-19 patients underwent comprehensive motor and sensory nerve conduction studies. Spearman's correlation and Kruskal–Wallis tests were used to examine the relationship between disease severity and electromyographic findings. ResultsOf the 170 patients in the study, 71.17% were male and 28.82% female, with an average age of 48 years; the subgroup of patients with severe clinical classification predominated at 68.23%. Spearman's correlation yielded values higher than 0.5 for all parameters analyzed concerning severity classification. A significant difference was found in the average of non-evoked motor and sensory nerves, motor nerves with latency, amplitude, and conduction velocity impairment, and affected muscles regarding critical classification. ConclusionOur study showed a relationship between the severity of COVID-19 and an increase in non-evoked motor and sensory nerves, impaired motor nerve latency, amplitude, and velocity, and more affected muscles, particularly in critical cases.

Toxoplasma gondii infection positively associated with schizophrenia: Evidences from UK Biobank cohort and case-controlled studies

Toxoplasma gondii (T. gondii) is an opportunistic pathogen affecting about 1/3 of world population. While often asymptomatic in immunocompetent individuals, it can lead to severe toxoplasmosis in immunocompromised patients. Recent research has unveiled a potential link between T. gondii infection and neuropsychiatric diseases. We implemented both a cohort study and a case control study to further identify this association. In the cohort study, we analyzed data from the UK Biobank database, which included 8814 individuals tested for T. gondii SAG1 antibodies and free of neuropsychiatric disorders at baseline. Among them, 22.52% (n = 1985) tested positive for SAG1 antibody. Over an average follow-up period of 12.26 years, Cox proportional hazards models and logistic regression analysis revealed a significant association between the SAG1 seropositivity at baseline and the incidence of schizophrenia (HR: 5.89; 95% CI: 1.69–20.53). In our case-control study, 239 patients diagnosed with schizophrenia and 455 healthy individuals were involved. Using the modified agglutination test (MAT) to detect T. gondii antibodies, logistic regression analysis showed a higher prevalence of T. gondii infection among schizophrenia patients (10.04%) compared to healthy controls (3.74%). T. gondii infection emerged as a significant risk factor for schizophrenia (OR: 3.33; 95% CI: 1.68–6.61). However, our investigations did not reveal a robust association between T. gondii infection and other neuropsychiatric conditions, including Alzheimer's disease, dementia, anxiety, depression, neurodegenerative disorders, and peripheral neurological disorders such as neurological and plexus disorders.

Serial electrodiagnostic testing: Utility and indications in adult neurological disorders.

Although existing guidelines address electrodiagnostic (EDX) testing in identifying neuromuscular conditions, guidance regarding the uses and limitations of serial (or repeat) EDX testing is limited. By assessing neurophysiological change longitudinally across time, serial electrodiagnosis can clarify a diagnosis and potentially provide valuable prognostic information. This monograph presents four broad indications for serial electrodiagnosis in adult peripheral neurological disorders. First, where clinical change has raised suspicion for a new or ongoing lesion, EDX reassessment for spatial spread of abnormality, involvement of previously normal muscle or nerve, and/or evolving pathophysiology can clarify a diagnosis. Second, where diagnosis of a progressive neuromuscular condition is uncertain, electrophysiological data from a second time point can confirm or refute suspicion. Third, to establish prognosis after a static nerve injury, a repeat study can assess the presence and extent of reinnervation. Finally, faced with a limited initial study (as when complicated by patient or environmental factors), a repeat EDX study can supplement missing or limited data to provide needed clarity. Repeat EDX studies carry certain limitations, however, such as with prognostication in the setting of remote or chronic lesions, sensory predominant fascicular injury, or mild axonal injury. Nevertheless, serial electrodiagnosis remains a valuable and underused tool in the diagnostic and prognostic evaluation of neuromuscular conditions.

Cellular and molecular mechanisms involved in the analgesic effects of botulinum neurotoxin: A literature review.

Botulinum neurotoxins (BoNTs), derived from Clostridium botulinum, have been employed to treat a range of central and peripheral neurological disease. Some studies indicate that BoNT may be beneficial for pain conditions as well. It has been hypothesized that BoNTs may exert their analgesic effects by preventing the release of pain-related neurotransmitters and neuroinflammatory agents from sensory nerve endings, suppressing glial activation, and inhibiting the transmission of pain-related receptors to the neuronal cell membrane. In addition, there is evidence to suggest that the central analgesic effects of BoNTs are mediated through their retrograde axonal transport. The purpose of this review is to summarize the experimental evidence of the analgesic functions of BoNTs and discuss the cellular and molecular mechanisms by which they can act on pain conditions. Most of the studies reviewed in this article were conducted using BoNT/A. The PubMed database was searched from 1995 to December 2022 to identify relevant literature.

The Role and Mechanism of Autoantibodies in Dysimmunity Related Neurological Diseases

Autoantibodies are antibodies produced by B cells capable of attacking their own tissues or organs after loss of immune tolerance. A large body of literature shows that autoantibodies play an important role in neurological diseases associated with immune abnormalities. Nowadays, neurological disorders are an important cause of disability and death in populations around the world, so it is important to study the role and mechanisms of autoantibodies in neurological disorders associated with immune abnormalities. The blood-brain barrier is biologically important for maintaining the normal physiological state of the central nervous system, and we have previously found that monoclonal autoantibodies of SLE origin can inhibit the expression of tight junction proteins in the blood-brain barrier. Our findings provide clues for the study of the role of autoantibodies in neurological disorders and greatly attract us to conduct a more in-depth and systematic review and synthesis. In this paper, we summarize the functions of autoantibodies in autoimmune and non-autoimmune diseases and focus on the roles and mechanisms of autoantibodies in immune-associated neurological disorders by taking central and peripheral neurological diseases as the entry points, which can provide new molecular targets and new theoretical basis for the specific diagnosis and targeted therapy of neurological diseases.

Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study

Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients with EGPA. This retrospective cohort study included patients with EGPA from 28 European referral centres of the European EGPA Study Group across six countries (Italy, France, UK, Russia, Spain, and Switzerland) who received benralizumab as any line of treatment between Jan 1, 2019, and Sep 30, 2022. We assessed the rates of complete response, defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] of 0) and a prednisone dose of up to 4 mg/day, in contrast to partial response, defined as a BVAS of 0 and a prednisone dose greater than 4 mg/day. Active disease manifestations, pulmonary function, variation in glucocorticoid dose, and safety outcomes were also assessed over a 12-month follow-up. 121 patients with relapsing-refractory EGPA treated with benralizumab at the dose approved for eosinophilic asthma were included (64 [53%] women and 57 [47%] men; median age at the time of beginning benralizumab treatment 54·1 years [IQR 44·2-62·2]). Complete response was reported in 15 (12·4%, 95% CI 7·1-19·6) of 121 patients at month 3, 25 (28·7%, 19·5-39·4) of 87 patients at month 6, and 32 (46·4%, 34·3-58·8) of 69 patients at month 12; partial response was observed in an additional 43 (35·5%, 27·0-44·8) patients at month 3, 23 (26·4%, 17·6-37·0) at month 6, and 13 (18·8%, 10·4-30·1) at month 12. BVAS dropped from 3·0 (IQR 2·0-8·0) at baseline to 0·0 (0·0-2·0) at months 3 and 6, and to 0·0 (0·0-1·0) at month 12. The proportion of patients with systemic manifestations, active peripheral neurological disease, ear, nose, and throat involvement, and pulmonary involvement decreased, with an improvement in lung function tests. Six patients relapsed after having a complete response. The oral prednisone (or equivalent) dose decreased from 10·0 mg/day (5·0-12·5) at baseline to 5·0 mg/day (3·6-8·5) at month 3 (p<0·01), to 5·0 mg/day (2·5-6·3) at month 6, and to 2·5 mg/day (0·0-5·0) at month 12 (p<0·0001). 19 (16%) of 121 patients had adverse events and 16 (13%) discontinued benralizumab. These data suggest that benralizumab could be an effective treatment for EGPA in real-life clinical practice. Further clinical trials are required to confirm the efficacy of benralizumab in patients with a higher baseline disease activity. None.

Recurrent Toe Walking in Pediatric Orthopedic Patients: Idiopathic vs Concomitant Sensory Processing Disorders

Category: Other Introduction/Purpose: The purpose of this study is to compare rates of recurrent toe-walking following operative intervention between idiopathic toe walkers and toe walkers with associated sensory processing/autism spectrum disorders. Methods: An IRB-approved retrospective review of patients at a single pediatric institution who underwent surgical treatment for toe-walking over a 12-year period was conducted. Children with peripheral or central neurologic disorders, muscle disorders, congenital foot/extremity deformities, prior ankle/foot surgery, and those not managed with an isolated triceps surae procedure were excluded. The remaining patients were divided into those with idiopathic toe-walking (ITW Group) and those with toe- walking associated with sensory processing/autism spectrum disorders (SPD Group). Recurrence of toe walking and need for additional surgery for recurrence were compared between cohorts. Recurrence rates and subsequent operations were assessed for each group. Multivariate regression and Fischer exact test were used to evaluate differences in group characteristics. Results: 106 patients met inclusion criteria. 29 patients (27%) had an associated sensory processing disorder, the remaining 77 patients comprised the ITW group. There were no differences between groups in length of follow-up (p=0.08) or type of initial surgery performed (p=0.48). The SPD group contained a significantly greater percentage of males (75% vs 56%, p=0.01) and were younger at the age of index surgery (8.5 vs 10 years, p=0.03). At an average follow-up time of 1.2 years, 11 patients (10%) developed clinical recurrence, of whom, 4 underwent a subsequent intervention. The SPD group had significantly higher rates of recurrence than idiopathic toe walkers (24% vs 5%, p=0.009). Multivariate regression analysis demonstrated that an underlying sensory processing disorder was an independent predictor of recurrence (p=0.018, OR=7.5). Conclusion: Clinical recurrence following the surgical treatment of toe-walking is over seven times greater in children with autism spectrum and/or other sensory processing disorders than idiopathic counterparts.

Neuropathic pain in patients with primary knee osteoarthritis: A cross-sectional study.

Neuropathic pain (NP) is believed to be a distinct subtype of pain associated with knee osteoarthritis (KO). This study aimed to determine the prevalence of NP in patients with primary KO and examine its correlation with various factors. A cross-sectional study was conducted on 195 patients with primary KO who did not have the following conditions: knee surgery, infection, rheumatic diseases, peripheral and central neurological diseases, patients who received treatment for neuropathic pain in the past 6 months, diabetes, renal failure, and alcoholism. NP was evaluated using two standardized questionnaires, the Douleur Neuropathique 4 questions (DN4) and the painDETECT questionnaire. The majority of patients were female (87.5%), with a mean age of 59.15 ± 7.62 years. NP was detected in 55.9% of patients according to the DN4 questionnaire and in 50.7% of patients according to the painDETECT questionnaire. The DN4 score was positively correlated with age (p=0.041; rs=0.145), visual analogue scale (VAS)-pain at rest (p=0.009; rs=0.188), VAS-pain at movement (p=0.017; rs=0.173), Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain score (p=0.030; rs=0.157), WOMAC stiffness score (p=0.000; rs=0.253), physical function WOMAC score (p=0.000; rs=0.271), total WOMAC score (p=0.000; rs=0.305), Lequesne score (p=0.002; rs=0.221), and negatively correlated with quadriceps circumference (p=0.008; rs=-0.210). Whereas, the painDETECT score was positively correlated with VAS-pain at movement (p=0.002; rs=0.220), WOMAC stiffness score (p=0.043; rs=0.147), physical function WOMAC score (p=0.017; rs=0.172), and total WOMAC score (p=0.012; rs=0.182). NP according to the DN4 was associated with quadriceps circumference (p=0.01), while the painDETECT score was associated with VAS- pain at movement scores (p=0.022) and total WOMAC score (P=0.001). This study found that NP is common among patients with primary KO and is associated with more painful pathology and functional impairment. These findings highlight the importance of recognizing and managing NP in this population to improve patient outcomes.

Cervical Debranching: Regional versus General Anesthesia for Carotid-Subclavian Bypass. A Single Center Experience

We report here the first cohort study comparing regional and general anaesthesia for left subclavian artery (LSA) revascularization. A single-centre retrospective cohort study was performed, including all consecutive patients who underwent cervical debranching with carotid-subclavian bypass before aortic repair from February 2018 to May 2022. Patients were divided into two groups according to the type of anesthesia: Regional anesthesia (RA) versus general anesthesia (GA). Primary endpoints included: 1) technical success of regional anesthesia, 2) neurological complications (stroke and peripheral neurological lesions). Secondary endpoints included postoperative bleeding, wound complications, 30-day reintervention rate, and midterm events. Eighty-three patients were included in the study. Mean age was 64 years (IQR:13.5) and 69% were male. Thirty-seven patients (44.5%) were performed under RA. Technical success of regional anesthesia was 89.2%. Two minor strokes (2.4%) were observed in the GA group (p=.199). Peripheral neurological disorders occurred in 4 patients (4.8%) (RA group n=1 (2.7%), GA group n=3 (6.5%), p=.491). 30-day complication rate was 27.7% (n=23, GA: n=15 (32.6%), RA: n=8 (21.6%), p=.266). 30-day re-intervention rate was 14.5% (n=12), ten bleeding complications (12%) (RA group n=3 (8.1%), GA group n=7 (15.2%), p=.323) and two seroma evacuations (2.4%) in the RA group. The incidence of superficial wound infections was n= 6 (7.2%) (RA group n=2 (5.4%), GA group n=4 (8.7%), p=.565). Median follow-up time was 22 months (IQR 22 min/max 1-44). In our cohort, regional anesthesia for carotid subclavian bypass surgery proved to be a feasible and effective anesthetic procedure compared with general anesthesia.

Konzepte der Sturzrisikoabschätzung bei neurogeriatrischen Patienten

Neurogeriatric patients are prone to falls. Particularly, patients with central neurological diseases (e. g., Parkinson's disease, cerebellar disorders) fall more often and more severe compared to patients with peripheral neurological disorders (e. g., peripheral neuropathy, bilateral vestibulopathy). Falls can lead to severe injuries with prolonged hospital treatment with subsequently impaired mobility, reduced quality of life and fear of falling. This article depicts general, clinical and mobility-based fall risk factors in neurogeriatric patients and gives an overview how to identify patients with a high risk of falling. Furthermore, a multimodal fall risk assessment is illustrated, which expands the diagnostic approach utilising clinical, instrument-based and mobile motion analysis.

Evidence for an Intrathecal Immunoglobulin Synthesis by Kappa Free Light Chains in Neurological Patients with an Isolated Band in Isoelectric Focusing.

The gold standard for detecting intrathecal immunoglobulin synthesis is the determination of the oligoclonal band (OCB) in the cerebrospinal fluid (CSF) using isoelectric focusing (IEF). Controversy still exists regarding the significance of an isolated band in the CSF. A highly promising alternative method for the assessment of intrathecal inflammation is the quantification of kappa free light chains (k-FLC). Our aim was to evaluate the clinical significance of quantitative k-FLC in patients with an isolated band in the CSF. Using the Human Kappa Freelite Mx Kit on a turbidimetric Optilite®, we quantified the k-FLCs in paired CSF and serum samples in 47 patients with a single band in IEF. We classified patients into 27× inflammatory neurological disorders (IND), 2× peripheral inflammatory neurological disorders (PIND), 9× non-inflammatory neurological disorders (NIND) and 9× symptomatic controls (SC) based on their medical diagnosis. k-FLC were below the lower measurement limit of the analyser (LML) in all SC and PIND, as well as in 8 out of 9 NIND and 11 IND. Only 1 NIND and 16 IND were above the LML, and of these, only 14 IND were above the upper discrimination limit (Qlim). A neuroinflammatory nature of the diseases can be indicated in many cases by positive k-FLC in patients with an isolated band in IEF. The measurement of k-FLC can support the diagnosis of neurological diseases if they are included in the routine work-up.

The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors.

Cancer immunotherapy represents a novel anticancer strategy that acts directly on the immune system, promoting its activation toward cancer cells to enhance its natural ability to fight cancer. Among various treatments currently used or investigated, chimeric antigen receptors (CAR) T-cell therapy and immune checkpoint inhibitors (ICIs) have consistently proven their efficacy. These innovations are progressively improving the standard of care in cancer treatment, yet they are hampered by novel neurological adverse events, attributing to neurologists a key role in the multidisciplinary oncological team. Indeed, neurotoxicity may develop in up to 77% of patients who received CAR T-cell therapy and usually presents with encephalopathy characterized by a predominant frontal lobe dysfunction. This neurotoxicity is related to cytokine release syndrome, a systemic hyperinflammatory condition triggered by CAR T-cells. On the other hand, following treatment with ICIs, unrestrained T-cells may lead to central and peripheral neurological disorders by antigen-directed autoimmunity. Notably, biological and clinical similarities have been underlined between neurotoxicity related to CAR T-cell therapy and neurological manifestations of cytokine storms (e.g. COVID-19-related encephalopathy), as well as between a subgroup of ICI-related neurological adverse events and paraneoplastic neurological syndromes. Therefore, these cancer immunotherapy-related neurological syndromes may provide an unprecedented, perhaps transitory, opportunity to shed light on the underlying pathogenic mechanisms of a wide spectrum of neurological syndromes and to push forward our knowledge in neuroimmunology.

The neurological complications after covid-19 in children

Studies have shown that during the pandemic period, children under 5 years of age accounted for 1.8% of COVID-19 cases. After covid complications are now a major concern and represent a new disease entity known as PIMS and MIS-C. Many studies have been conducted on the pathomechanism of the virus and the clinical manifestations it causes in adults, including neurological complications.&#x0D; Symptoms are mainly associated with central and peripheral neurological disorders, ranging from mild (headache, fever, cough, pharyngitis, rhinitis and anosmia) to severe (stroke or Guillain-Barré syndrome). Dyspnoea or respiratory failure is seen in approximately 11.7% of young patients. Although SARS-CoV-2 mainly occupies the respiratory system, about 10% report gastrointestinal symptoms. CT abnormalities of the chest of children are less frequent and milder than in adults, and include opacities of frosted glass and patchy shadows. In many cases, elevated CK-MB levels have also been noted, indicating possible myocardial damage.&#x0D; Children and adolescents contribute to an increasing proportion of all Covid-19 cases. It can be due to the emergence of highly infectious variants of the virus. Many drugs have been tried in children both antiviral, antimalarial, corticosteroids and intravenous immunoglobulin or selective cytokine brokers. The only effective method of prophylaxis is two doses of BNT162b2 vaccine given 21 days apart.

Clinical and laboratory evaluation of sicca complaints: distinctive aspects of primary, secondary and non-Sjogren syndrome

BackgroundSjögren Syndrome (SS) is a systemic autoimmune disease with a wide spectrum of manifestations that can lead to misdiagnosis. This study describes and compares demographic, clinical, serological, and histopathological data from subjects with SS and non-Sjögren Syndrome (NSS). It also details specific features within the primary SS (pSS) and secondary SS (sSS) groups identifying sub-groups.MethodsThe sample included individuals referred to an academic medical center in Brazil for investigation of SS from 2012 to 2020. Patients were retrospectively classified as primary SS (pSS), secondary SS (sSS), or NSS, based on the American-European Consensus Group criteria (AECG-2002), after multi-professional clinical and laboratory evaluation.ResultsA total of 676 individuals were screened and 510 (75.4%) completed the assessments; 198 patients were classified as pSS, 149 as sSS, and 163 as NSS. Symptoms and glandular dysfunction tests were similar in the groups. Concerning pSS, extraglandular manifestations were present in 59% of patients; the elderly had more dry symptoms and peripheral neurological disorders; and 2.5% developed non-Hodgkin lymphoma. In sSS, each overlap promoted distinct clinical and laboratory variants. Several alternative diagnoses were identified as a cause of sicca complex in NSS group.ConclusionsThe diagnosis of SS remains a challenge behind dryness. Up to 31% of the suspected cases had other conditions associated to the symptoms. Histopathological analysis of LSG and SSa determined the diagnostic. Aging in pSS and overlap disease in sSS were responsible for distinct phenotypes and characteristic sub-groups in SS.

Evaluation of hand-arm vibration(HAV) exposure levels among grounds maintenance workers: An observational human exposure measurement study.

Evaluation of hand-arm vibration(HAV) exposure levels among grounds maintenance workers: An observational human exposure measurement study.

Case series on the Charcot neuroarthropathy in hands after cervical central cord syndrome

BackgroundCharcot neuroarthropathy (CNA) of the upper extremity occurs most frequently in shoulders. However, CNA in the hands is uncommon and seldom be reported. The onset of CNA is usually insidious. If this process continues undetected, it can result in joint deformity, ulceration and/or superinfection, loss of function, and amputation or even death. In this article, we are going to present three cases of CNA in the hands of individuals with cervical spinal cord injury (SCI) with central cord syndrome.Case presentationThree male individuals with cervical spinal stenosis contracted tetraplegia (American Spinal Injury Association Impairment Scale Grade D, D, and B) due to spinal cord contusion after a trauma and developed hand swelling without pain 2 to 3 months after their SCI. X-ray showed degenerative joint changes in the hands. CNA was considered due to the patient’s history of cervical SCI, loss of motor function and sensation, symptoms of painless swelling, physical examination, and X-ray findings. The self-care sub scores of Spinal Cord Independence Measure III improved slightly only during rehabilitation and follow-up due to poor hand function.ConclusionsCNA may develop after a central or peripheral neurological disorder. Nearly every joint of the body can be affected and the lower limbs are the most frequently involved. However, CNA of the hand is rare. We present three patients with CNA in the hands after cervical SCI and review the features and early differential diagnosis of CNA. Currently there is no specific treatment available. Therefore, early identification of CNA and adequate protection to the affected joints seem important.

COVID-19 and its impact on the brain and Mind- A conceptual model and supporting evidence.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that is causing the ongoing coronavirus disease 2019 (COVID-19) pandemic, was first reported in late 2019. Since then, an unprecedented amount of new knowledge has emerged about this virus and its treatment. Although the reported symptoms of COVID-19 are primarily respiratory with acute respiratory distress syndrome, SARS-CoV-2 has also been shown to affect other organs, including brain, and there are growing reports of neuropsychiatric symptoms due to COVID-19. There are two suggested pathways for how COVID-19 can affect the brain and mind: the direct impact on the brain and impact mediated via stress. Direct impact on the brain is manifested as encephalitis/encephalopathy with altered mental status (AMS) and delirium. In this paper, we summarize evidence from studies of previous outbreaks and current data from the COVID-19 pandemic that describe how COVID-19 is associated with an increased prevalence of anxiety, stress, poor sleep quality, obsessive-compulsive symptoms, and depression among the general population during the pandemic. In addition, we summarize the current evidence that supports how COVID-19 can also impact the CNS directly and result in delirium, cerebrovascular events, encephalitis, unspecified encephalopathy, AMS, or peripheral neurologic disorders.Supplementary InformationThe online version contains supplementary material available at 10.1007/s11126-022-09980-9.

Development of magnetic resonance imaging of brachial plexus neuralgia.

As the incidence of peripheral neurological diseases increases, the precise display of nerves becomes important in imaging examinations. Among them, the pain caused by brachial plexus neuropathy is very prominent, and the magnetic resonance imaging of nerve is quite complex and messy. This paper will systematically elaborate from the aspects of brachial plexus neuropathy, morphological and functional imaging, and post-processing.

The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study

Background: Cerebrospinal fluid (CSF) free light chains (FLCs) can be an alternative assay to oligoclonal bands (OCBs) in inflammatory neurological disorders, but threshold has no consensus. Objective: To assess the diagnostic accuracy of CSF FLCs in multiple sclerosis (MS) and other neurological diseases. Methods: A total of 406 patients from five Italian centers. FLCs were measured in CSF and serum using Freelite MX assays on Optilite. Results: A total of 171 patients were diagnosed as MS, 154 non-inflammatory neurological diseases, 48 inflammatory central nervous system (CNS) diseases, and 33 peripheral neurological diseases. Both kFLC and λFLC indices were significantly higher in patients with MS compared to other groups (p < 0.0001). The kFLC index ⩾ 6.4 is comparable to OCB for MS diagnosis (area under the receiver operating characteristic curve (AUC) = 0.876; sensitivity 83.6% vs 84.2%; specificity 88.5% vs 90.6%). λFLC index ⩾ 5 showed an AUC of 0.616, sensitivity of 33.3% and specificity of 90.6%. In all, 12/27 (44.4%) MS patients with negative OCB had kFLC index ⩾ 6.4. Interestingly, 37.5% of 24 patients with a single CSF IgG band showed high kFLC index and 12.5% positive λFLC index. Conclusion: Our findings support the diagnostic utility of FLC indices in MS and other CNS inflammatory disorders, suggesting a combined use of FLC and OCB to help clinicians with complementary information.

Predictors of Neurological Presentations of COVID-19 Infected Patients in South Egypt, Aswan Governorate: A Single Center Study.

BackgroundCOVID-19 is a complex multisystem disease comprising multiple organ dysfunctions including neurologic manifestations. Some COVID-19 patients may present neurologic symptoms as the initial presentations of the disease.ObjectiveWe aim at investigating the frequency and the predictors of neurological manifestations in patients with confirmed COVID-19.MethodsA retrospective cross-sectional single-center study analyzed COVID-19 positive patients with neurological manifestations from March to June 2020, in Aswan Governorate, Egypt. Demographic data, clinical, radiological and laboratory findings, comorbidities, and treatments were collected and analyzed.ResultsOut of the 905 confirmed COVID-19 patients; 422 patients (46.6%) had neurological manifestations and fulfilled the study inclusion criteria, 223 patients (52.8%) had central neurological disorders (CNS), 107 (25.4%) had peripheral neurological disorders (PNS), and 92 (21.8%) patients had non-specific neurological disorders. Age >50 years, diabetes mellitus, CORAD> III and smoking were predictors for neurological system affection.ConclusionCOVID-19 infection has been associated with numerous neurological deficits, especially in elderly patients. Central nervous system disorders were the most prevalent deficit with predominance of cerebrovascular events.